MX2016008272A - Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment. - Google Patents

Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment.

Info

Publication number
MX2016008272A
MX2016008272A MX2016008272A MX2016008272A MX2016008272A MX 2016008272 A MX2016008272 A MX 2016008272A MX 2016008272 A MX2016008272 A MX 2016008272A MX 2016008272 A MX2016008272 A MX 2016008272A MX 2016008272 A MX2016008272 A MX 2016008272A
Authority
MX
Mexico
Prior art keywords
hsdd
trazodone
bupropion
methods
sexual desire
Prior art date
Application number
MX2016008272A
Other languages
Spanish (es)
Inventor
E Pyke Robert
Clayton Anita
Taylor Segraves Robert
Derogatis Leonard
Katz Molly
Meston Cindy
G Sitchon Nicholas
Original Assignee
S1 Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016008272(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S1 Biopharma Inc filed Critical S1 Biopharma Inc
Publication of MX2016008272A publication Critical patent/MX2016008272A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to methods of treating women for hypoactive sexual desire disorder (HSDD) with oral daily treatments of low dose and high dose combinations of trazodone and bupropion.
MX2016008272A 2016-06-17 2016-06-20 Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment. MX2016008272A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351904P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
MX2016008272A true MX2016008272A (en) 2017-12-18

Family

ID=57758862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008272A MX2016008272A (en) 2016-06-17 2016-06-20 Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment.

Country Status (9)

Country Link
KR (1) KR20170142797A (en)
AR (2) AR105047A1 (en)
AU (1) AU2016204151A1 (en)
CA (1) CA2933921A1 (en)
CL (1) CL2016001597A1 (en)
MX (1) MX2016008272A (en)
PE (1) PE20180023A1 (en)
UY (1) UY36742A (en)
WO (1) WO2017218018A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897864A (en) * 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
KR20070014184A (en) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 New pharmaceutical compositions for the treatment of sexual disorders ii
EP1998773A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware New therapeutic combinations for the treatment of depression
CA2881388A1 (en) * 2012-08-06 2014-02-13 S1 Pharmaceuticals, Inc. Treatment regimens

Also Published As

Publication number Publication date
AR105047A1 (en) 2017-08-30
CL2016001597A1 (en) 2017-10-06
KR20170142797A (en) 2017-12-28
AU2016204151A1 (en) 2018-01-18
UY36742A (en) 2016-12-30
PE20180023A1 (en) 2018-01-09
AR105087A1 (en) 2017-09-06
CA2933921A1 (en) 2017-12-17
WO2017218018A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
CL2018001152A1 (en) Compositions and methods for cancer treatment
EA201790737A1 (en) COMBINED THERAPY
MX2017010150A (en) Recombinant probiotic bacteria.
EA201690206A1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
MX2015011783A (en) Methods of treatment of pediatric solid tumor.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2023007212A (en) Epinephrine spray formulations.
NZ723884A (en) Methods of treating alzheimer’s disease
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2023010501A (en) Dantrolene prodrugs and methods of their use.
EA201692284A1 (en) NIACINAMIDE FOR STIMULATING THE PRODUCTION OF ANTIMICROBIAL PEPTIDES
JOP20190241B1 (en) Epinephrine spray formulations
MX2020001727A (en) Combination therapy.
MX2017000306A (en) Methods for treating hypotension.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
GEP20186939B (en) Medical treatments based on anamorelin
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
MX2017010654A (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders.
EA201792560A1 (en) NANOPARTICLES FOR APPLICATION AS A THERAPEUTIC VACCINE
MX2019004804A (en) Treatment of prurigo nodularis.
MX2016008272A (en) Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment.
MX2023011202A (en) Rara agonists for the treatment of aml and mds.
NZ727412A (en) Methods of treating neurodevelopmental diseases and disorders
UA116659C2 (en) Application of adsorbed drone brood homogenate and of vitamin d3 or d-group vitamins and/or active metabolites thereof for preventing and treating viral diseases
MX2015001695A (en) Treatment regimens.